SCHEMBL4228469

SCHEMBL4228469

OCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
THRB P10828 1/20 0.35
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP9 P14780 1/20 0.30
MMP8 P22894 1/20 0.30
MMP13 P45452 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8617976 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL63212 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL62768 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL6906534 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL8614275 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL3133329 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL62965 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL4123177 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL17997086 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1
SCHEMBL4265800 1.00 LMNA (0.35) LMNATHRBCA1CA2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109054795-B Preparation method of hybrid fluorine-containing surfactant for ultra-low permeability reservoir flooding 成都理工大学 2020-10-13 CN disclosed
US-9879153-B2 Anti-icing composite WANG LIANG (US) 2018-01-30 US disclosed
EP-2096099-B1 Purification of fluorinated alcohols DU PONT (US) 2016-04-13 EP disclosed
US-20160009971-A1 Anti-Icing Composite WANG LIANG (US) 2016-01-14 US disclosed
US-20150110814-A1 COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES PSMA DEVELOPMENT COMPANY, LLC (US) 2015-04-23 US disclosed
EP-1807382-B1 PURIFICATION OF FLUORINATED ALCOHOLS DU PONT (US) 2011-12-21 EP disclosed
EP-2096099-A1 Purification of fluorinated alcohols E.I. DU PONT DE NEMOURS AND COMPANY (US) 2009-09-02 EP disclosed
US-7138551-B2 Purification of fluorinated alcohols E. I. DU PONT DE NEMOURS AND COMPANY (US) 2006-11-21 US disclosed
US-20060100464-A1 Purification of fluorinated alcohols THE CHEMOURS COMPANY FC, LLC 2006-05-11 US disclosed
US-6002048-A Fluorine-containing ether compound and gelling agent containing the same KAO CORPORATION (JP) 1999-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150110814-A1 COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES CD47, CD4, PSMA1 LMNA 4423/4885THRB 1918/4885CA1 25/4885
US-20060100464-A1 Purification of fluorinated alcohols ADH1A, ADH1C, ADH5 LMNA 1163/4885THRB 85/4885CA1 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.